What DefenCath does is that it prevents the risk of infection for patients using central venous catheters (CVCs ... The market cap is at $466.7 million as at 27 March 2025, for a share price ...

DefenCath reduces the occurrence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. It was approved ...

The FDA shared an alert that BD (NYSE: BDX) and its Bard subsidiary warned customers of an issue with certain intravascular ...

Objective: Following the introduction and widespread use of central venous catheters (CVCs) in adults, these devices are being used with increasing frequency in the pediatric population.

Li, C.T., Qian, Z., Wang, Y.Q.,Long, X.Q. andMao,H.M. (2025) Advances in the Study of Venous Thrombosis Associated with Peripherally Inserted Central Venous Catheters. Journal of Biosciences and ...

A study in patients with solid tumors found that CRBSI is significantly linked to mortality in patients with PICCs, whereas CRT and CRLC are not significant risk factors.

Meanwhile, North Central league club Birchip-Watchem and Golden Rivers league club Hay were also hit with “formal reprimands” for breaches of the salary cap. They both must attend this year ...

pulmonary embolism or upper-limb or central venous catheter–related thrombosis, incidental proximal deep-vein thrombosis, or incidental pulmonary embolism. Venous thromboembolism–related death ...

CorMedix ( CRMD 1.02%) Q4 2024 Earnings Call Mar 25, 2025, 8:30 a.m. ET Good day, and welcome to the CorMedix Inc. fourth-quarter and full-year 2024 financial results conference call. All participants ...

CVC = Central venous catheter; SBP = Systolic blood pressure Adapted with permission from [7,11,12]. Jean-Luc Pagani and Philippe Eggimann, Department of Adult Intensive Care Medicine & Burn ...